Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
DNA repair overview risk and intensity
DNA structure
DNMT
dNTPs
docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)
dose-escalation limiting toxicity (DLT)
dose-limiting toxicity (DLT)
DPD
DRESS
DRR
Drug approval and regulatory issues additional pharmacology considerations dose refinement studies drug-drug interaction food effect hepatic impairment INDâchr(128)”enabling nonclinical studies for cancer drugs QT prolongation recommended phase 2 dose (RP2D) renal impairment
Drug developments clinical trial definitions clinical trial facts and phases new active substance launches from 2011 to 2016 by indication overview patient selection and study design protocols RECIST 1.1, the WHO, and the irRC Criteria
drug reaction with eosinophilia and systemic symptoms (DRESS) Answer 14.2 Question 14.2
DS
DTIC
dTNP. see deoxyribonucleotide triphosphates (dTNP)
ductal carcinoma in situ (DCIS)
dUMP
DVT
E1
E2
E3
ECM
EFS
EGFR
EKG
electrocardiogram (EKG)
endoplasmic reticulum (ER)
epidermal growth factor receptor (EGFR)
Epigenetic modulators bromodomain inhibitors chromatin structure and epigenetic marks clinical use overview treatment goal